Application Data
(A microtiter plate was coated overnight with recombinant human VEGF-A at a concentration of 5 ug/ml. After washing and blocking with PBST+5% BSA, 10% human serum was added spiked with increasing concentrations of bevacizumab. Detection was performed using Human Anti-Ranibizumab Antibody, clone AbD29865 (HCA307, cross-reactive with bevacizumab) at a concentration of 2 mug/ml and a rat anti-DYKDDDDK-tag antibody in HISPEC Assay Diluent (BUF049A) followed by QuantaBlu Fluorogenic Peroxidase Substrate. Data are shown as the mean of three measurements.)
VEGF-A recombinant protein
Recombinant Human VEGF-A
Gene Names
VEGFA; VPF; VEGF; MVCD1
Applications
ELISA
Purity
>=90% determined by SDS-PAGE under reducing conditions and visualized by coomassie blue stainingPurified by affinity chromatography
Synonyms
VEGF-A; N/A; Recombinant Human VEGF-A; VEGF-A recombinant protein
Host
E Coli
Purity/Purification
>=90% determined by SDS-PAGE under reducing conditions and visualized by coomassie blue staining
Purified by affinity chromatography
Purified by affinity chromatography
Form/Format
Lyophilized
Concentration
0.5 mg/ml after reconstitution (varies by lot)
Sequence Length
171
Applicable Applications for VEGF-A recombinant protein
ELISA
Source
Human
Reconstitution
Centrifuge vial prior to reconstitution. Reconstitute to 0.5 mg/ml by adding 0.4 ml ddH2O.
Pre-Lyophilization Buffer
20 mM Phosphate Buffer, 0.1 M Sodium Chloride
Preservative Stabilizers
1% Trehalose
Preparation and Storage
Prior to reconstitution store at -70 degree C. Following reconstitution store at -20 degree C.
This product should be stored undiluted. Storage in frost-free freezers is not recommended. Avoid repeated freezing and thawing as this may denature the protein.
This product should be stored undiluted. Storage in frost-free freezers is not recommended. Avoid repeated freezing and thawing as this may denature the protein.
Application Data
(A microtiter plate was coated overnight with recombinant human VEGF-A at a concentration of 5 ug/ml. After washing and blocking with PBST+5% BSA, 10% human serum was added spiked with increasing concentrations of bevacizumab. Detection was performed using Human Anti-Ranibizumab Antibody, clone AbD29865 (HCA307, cross-reactive with bevacizumab) at a concentration of 2 mug/ml and a rat anti-DYKDDDDK-tag antibody in HISPEC Assay Diluent (BUF049A) followed by QuantaBlu Fluorogenic Peroxidase Substrate. Data are shown as the mean of three measurements.)
Application Data
(A microtiter plate was coated overnight with recombinant human VEGF-A at a concentration of 5 ug/ml. After washing and blocking with PBST+5% BSA, 10% human serum was added spiked with increasing concentrations of bevacizumab. Detection was performed using Human Anti-Ranibizumab Antibody, clone AbD29865 (HCA307, cross-reactive with bevacizumab) at a concentration of 2 mug/ml and a rat anti-DYKDDDDK-tag antibody in HISPEC Assay Diluent (BUF049A) followed by QuantaBlu Fluorogenic Peroxidase Substrate. Data are shown as the mean of three measurements.)
Application Data
(A microtiter plate was coated overnight with recombinant human VEGF-A at a concentration of 5 ug/ml. After washing and blocking with PBST+5% BSA, 10% human serum was added spiked with increasing concentrations of ranibizumab. Detection was performed using Human Anti-Ranibizumab Antibody, clone AbD29928 (HCA304) at a concentration of 2 ug/ml and a rat anti-DYKDDDDK-tag antibody in HISPEC Assay Diluent (BUF049A) followed by QuantaBlu Fluorogenic Peroxidase Substrate. Data are shown as the mean of three measurements)
Application Data
(A microtiter plate was coated overnight with recombinant human VEGF-A at a concentration of 5 ug/ml. After washing and blocking with PBST+5% BSA, 10% human serum was added spiked with increasing concentrations of ranibizumab. Detection was performed using Human Anti-Ranibizumab Antibody, clone AbD29928 (HCA304) at a concentration of 2 ug/ml and a rat anti-DYKDDDDK-tag antibody in HISPEC Assay Diluent (BUF049A) followed by QuantaBlu Fluorogenic Peroxidase Substrate. Data are shown as the mean of three measurements)
Related Product Information for VEGF-A recombinant protein
Recombinant Human VEGF-A. Vascular endothelial growth factor alpha forms a homodimer and is a potent stimulator of angiogenesis of both normal and cancerous cells. It acts as a regulator of vasculogenesis, angiogenesis and endothelial cell growth. VEGF-A is secreted by many different cell types such as endothelial cells (Nissen et al. 1998), smooth muscle cells (Brogi et al. 1994), neutrophils (Gaudry et al. 1997), platelets (Banks et al. 1998), macrophages and 60% of all tumours (Berse et al. 1992). The sequence of this recombinant protein product is amino acid (aa) 27-aa 141 + CDKPRR but deficient from aa 142-226, and it is closest to isoform 121. Isoform 121 and 111 lack exons 6 and 7, and for this reason neither of these isoforms bind to the extracellular matrix (Krilleke et al. 2017). This product has been demonstrated for use, in a pharmacokinetic (PK) antigen capture ELISA with the monoclonal antibody drugs ranibizumab and bevacizumab using anti-ranibizumab antibodies for detection.
NCBI and Uniprot Product Information
NCBI GI #
NCBI GeneID
NCBI Accession #
NCBI GenBank Nucleotide #
UniProt Accession #
Molecular Weight
Predicted: 14 kDa
NCBI Official Full Name
vascular endothelial growth factor A isoform q
NCBI Official Synonym Full Names
vascular endothelial growth factor A
NCBI Official Symbol
VEGFA
NCBI Official Synonym Symbols
VPF; VEGF; MVCD1
NCBI Protein Information
vascular endothelial growth factor A
UniProt Protein Name
Vascular endothelial growth factor A
UniProt Gene Name
VEGFA
UniProt Synonym Gene Names
VEGF; VEGF-A; VPF
UniProt Entry Name
VEGFA_HUMAN
Similar Products
Product Notes
The VEGF-A vegfa (Catalog #AAA50377) is a Recombinant Protein produced from E Coli and is intended for research purposes only. The product is available for immediate purchase. AAA Biotech's VEGF-A can be used in a range of immunoassay formats including, but not limited to, ELISA. Researchers should empirically determine the suitability of the VEGF-A vegfa for an application not listed in the data sheet. Researchers commonly develop new applications and it is an integral, important part of the investigative research process. It is sometimes possible for the material contained within the vial of "VEGF-A, Recombinant Protein" to become dispersed throughout the inside of the vial, particularly around the seal of said vial, during shipment and storage. We always suggest centrifuging these vials to consolidate all of the liquid away from the lid and to the bottom of the vial prior to opening. Please be advised that certain products may require dry ice for shipping and that, if this is the case, an additional dry ice fee may also be required.Precautions
All products in the AAA Biotech catalog are strictly for research-use only, and are absolutely not suitable for use in any sort of medical, therapeutic, prophylactic, in-vivo, or diagnostic capacity. By purchasing a product from AAA Biotech, you are explicitly certifying that said products will be properly tested and used in line with industry standard. AAA Biotech and its authorized distribution partners reserve the right to refuse to fulfill any order if we have any indication that a purchaser may be intending to use a product outside of our accepted criteria.Disclaimer
Though we do strive to guarantee the information represented in this datasheet, AAA Biotech cannot be held responsible for any oversights or imprecisions. AAA Biotech reserves the right to adjust any aspect of this datasheet at any time and without notice. It is the responsibility of the customer to inform AAA Biotech of any product performance issues observed or experienced within 30 days of receipt of said product. To see additional details on this or any of our other policies, please see our Terms & Conditions page.Item has been added to Shopping Cart
If you are ready to order, navigate to Shopping Cart and get ready to checkout.